Ginsenoside Rg3 has effects comparable to those of ginsenoside re on diabetic kidney disease prevention in db/db mice by regulating inflammation, fibrosis and PPARγ
Molecular Medicine Reports · 2023
DOI: 10.3892/mmr.2023.12971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Medicine Reports, 2023. Verfasst von Zhe Sui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Management Medical Center, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Ginsenoside Rg3 (Rg3) is an adjuvant antitumor drug, while ginsenoside Re (Re) is an adjuvant antidiabetic drug. Our previous studies demonstrated that Rg3 and Re both have hepatoprotective effects in db/db mice. The present study aimed to observe the renoprotective effects of Rg3 on db/db mice, with Re as the control. The db/db mice were randomly assigned to receive daily oral treatment with Rg3, Re or vehicle for 8 weeks. Body weight and blood glucose were examined weekly. Blood lipids, creatinine, and BUN were examined by biochemical assay. Hematoxylin and eosin and Masson staining were used for pathological examination. The expression of peroxisome proliferator‑activated receptor gamma (PPARγ) and inflammation and fibrosis biomarkers was examined by immunohistochemical and reverse transcription‑quantitative PCR. Although neither had a significant effect on body weight, blood glucose or lipids, Rg3 and Re were both able to decrease the creatinine and blood urea nitrogen levels of db/db mice to levels similar to those of wild type mice and inhibit pathological changes. The expression of PPARγ was upregulated and biomarkers of inflammation and fibrosis were downregulated by Rg3 and Re. The results showed that the potential of Rg3 as a preventive treatment of diabetic kidney disease was similar to that of Re.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Management Medical Center, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China.
- Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China.
- Pharmacological Experiment Center, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China.
- Department of Pharmacy, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China.
Zitieren
APA
Sui, Z., Sui, D., Li, M., Yu, Q., Li, H., & Jiang, Y. (2023). Ginsenoside Rg3 has effects comparable to those of ginsenoside re on diabetic kidney disease prevention in db/db mice by regulating inflammation, fibrosis and PPARγ. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2023.12971
Vancouver
Sui Z, Sui D, Li M, Yu Q, Li H, Jiang Y. Ginsenoside Rg3 has effects comparable to those of ginsenoside re on diabetic kidney disease prevention in db/db mice by regulating inflammation, fibrosis and PPARγ. Molecular Medicine Reports. 2023. doi:10.3892/mmr.2023.12971
BibTeX
@article{Sui2023,
author = {Sui, Zhe and Sui, Dayun and Li, Min and Yu, Qian and Li, Hongjun and Jiang, Yichuan},
title = {Ginsenoside Rg3 has effects comparable to those of ginsenoside re on diabetic kidney disease prevention in db/db mice by regulating inflammation, fibrosis and PPARγ},
journal = {Molecular Medicine Reports},
year = {2023},
doi = {10.3892/mmr.2023.12971}
}
EUVIMED